Scalp Cooling Preserved Hair in Breast Cancer Chemotherapy

Key Takeaways

• In 82 patients with early-stage breast cancer receiving 4 cycles of epirubicin/cyclophosphamide followed by 12 weekly paclitaxel applications and standardized scalp cooling, 52% (43/82) maintained a posttreatment hair mass index of 50 or higher, the study threshold for absence of visible alopecia.
• Exploratory analyses linked better hair retention with less hair shaft damage and larger baseline shaft diameter, while posttreatment quality of life was independently associated with baseline quality of life and subjective scalp-cooling appraisal rather than with measured hair mass index change.

In 52% (43/82) of patients, visible hair retention remained measurable after anthracycline-taxane chemotherapy with standardized scalp cooling, yet posttreatment quality of life did not align simply with the amount of preserved hair. In a prospective single-arm JMIR Cancer scalp-cooling study, all participants had early-stage breast cancer, received the same curative-intent regimen, and underwent a uniform cooling approach designed to limit alopecia during treatment. The findings moved beyond visible hair retention alone by pairing objective hair measurements with structural hair assessment and patient-reported psychosocial outcomes.

All patients received 4 cycles of epirubicin/cyclophosphamide followed by 12 weekly paclitaxel applications, with scalp cooling delivered using a setup that maintained scalp temperature below 22 °C. The investigators defined 3 hair mass index end points: posttreatment HMI, HMI 50 or higher as the threshold for no visible alopecia, and change from baseline. Together, those end points describe how much hair was present after treatment, whether visible alopecia was avoided, and how far each patient shifted from pretreatment status. Because the cohort had no untreated comparison group, the results describe within-cohort outcomes rather than comparative treatment effects.

In exploratory models, the authors report nominal associations between greater hair shaft damage and lower posttreatment HMI (β=−.29, P=.046) and between larger baseline hair shaft diameter and HMI 50 or higher (OR 1.12, 95% CI 1.04-1.27; P=.02). The quality-of-life analysis showed a different pattern: posttreatment quality of life was independently associated with baseline quality of life, β=.41 and P<.001, and subjective scalp-cooling appraisal, β=.53 and P<.001, whereas HMI change was not independently associated; adjusted R² was 0.48. The authors presented these findings as associations in an exploratory single-arm analysis, and some modeled variables were assessed after treatment without formal multiplicity adjustment.

Across the reported hair mass index outcomes and microscopy analyses, light microscopy, scanning electron microscopy, and transmission electron microscopy identified treatment-associated shaft surface and pigmentary alterations, including cuticle lifting, focal cuticle disruption, longitudinal cortical translucencies, tapering, and melanosome-related changes. Ultrastructural analyses were available in a consecutive 52-patient subset because of technical-resource constraints. The cohort was single-center and single-arm, lacked an untreated control group, and offered limited precision for some estimates; the authors also reported that no increased risk of scalp metastasis was observed. Even with standardized cooling, the observed picture remained multidimensional, spanning visible hair retention, shaft-level alteration, and psychosocial appraisal.

Clinician Questions

How often did scalp cooling prevent visible alopecia during epirubicin/cyclophosphamide followed by weekly paclitaxel in early-stage breast cancer?

Among 82 patients with early-stage breast cancer receiving 4 cycles of epirubicin/cyclophosphamide followed by 12 weekly paclitaxel applications plus standardized scalp cooling, 52% (43/82) had posttreatment HMI ≥50, which the investigators defined as absence of visible alopecia.

Which hair-related factors were associated with better scalp-cooling outcomes in this breast cancer cohort?

In this single-arm early-stage breast cancer cohort receiving anthracycline-taxane chemotherapy with scalp cooling, greater increase in hair shaft damage was associated with lower posttreatment HMI, with β=−.29 and P=.046, and larger baseline hair shaft diameter was associated with higher odds of maintaining HMI ≥50, with OR 1.12, 95% CI 1.04-1.27, and P=.02. The investigators reported these as exploratory associations rather than causal predictors.

Was posttreatment quality of life more closely associated with hair retention or with scalp-cooling appraisal during chemotherapy-induced alopecia prevention?

In patients receiving scalp cooling during epirubicin/cyclophosphamide followed by weekly paclitaxel, posttreatment quality of life was independently associated with baseline quality of life, with β=.41 and P<.001, and with subjective scalp-cooling appraisal, with β=.53 and P<.001, whereas HMI change was not independently associated; adjusted R² was 0.48. The reported relationship was associative, not causal.

What structural hair changes were documented despite scalp cooling during highly alopecia-inducing chemotherapy?

During scalp cooling for highly alopecia-inducing chemotherapy in early-stage breast cancer, light microscopy, scanning electron microscopy, and transmission electron microscopy documented treatment-associated shaft surface and pigmentary alterations, including cuticle lifting, focal cuticle disruption, longitudinal cortical translucencies, tapering, and melanosome-related changes. Scanning electron microscopy and transmission electron microscopy data were available from a consecutive 52-patient subset processed for ultrastructural analysis.